Ceregene - Newsroom

Ceregene in the News

4.11	Gene Therapy Improved Parkinson's Symptoms
4.11	Thousands Walk in Support of the Parkinson's Community at the 2011 Parkinson's Unity Walk
4.11	Neurotrophic Factor Promising for PD in Early Phase - Again • View the poster
3.11	Michael J Fox Foundation: Clinical trials update call with Drs. Sherer and Standaert
3.11	Study Examines Experimental Parkinson's Treatment
2.11	Gene therapy finds its niche Gene therapy is finally poised to make a contribution to the treatment of debilitating, highly penetrant genetic diseases that have proved intractable to other regimens.
11.10	Parkinson's Action Network (PAN) New Clinical Trial Begins: Ceregene recently launched a new trial for its CERE-120 treatment. Learn more about the trial and hear from Dr. Raymond T. Bartus, Executive Vice President and Chief Scientific Officer at Ceregene, on how you can participate!
10.10	PDTrials.org Clinical Research News: Promising Developments in Gene Transfer Drug, CERE-120. Download (PDF 67kb )
10.10	Ceregene in the News "ABC Nightline...Alzheimers Breakthrough?"

09.10	Biotechnology: Crossing the barrier
02.08	Hopes High for Experimental Alzheimer's Treatment
03.07	Ceregene Bets on Better Delivery
02.07	Gene Therapy: Science in Slow Motion
01.07	Accepting the Risk in Hopes of a Cure
07.06	Central Nervous System Remains a Large Target for Novel Therapies (PDF 350k)
04.06	Alzheimer’s Trial Update
12.05	Gene therapy appears to relieve Parkinson's symptoms
11.05	Gene Therapy Is Respectable Again
09.05	Gene therapy gets a second chance
04.05	Boston Globe: Investors reconsider genetic therapies
01.05	Using gene therapy to treat Alzheimer's disease

For media related questions or to request information, please send an e-mail to media@ceregene.com